Protein clue may predict thyroid cancer treatment success
NCT ID NCT07314255
First seen Jan 06, 2026 · Last updated Apr 28, 2026 · Updated 17 times
Summary
This study examines tissue samples and medical records from 60 people with papillary thyroid cancer who received radioactive iodine (I-131) therapy. Researchers compare those who responded well to treatment with those who did not, focusing on levels of a protein called Trop2. The goal is to understand why some cancers become resistant to I-131 therapy, which could help guide future treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TROP2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jiangxi Cancer Hospital
Nanchang, Jiangxi, 330000, China
Conditions
Explore the condition pages connected to this study.